TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10996756

Group type: EXPERIMENTAL
Intervention: Antispasmodic drugs (Buscopan)
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Buscopan
Number of subjects: 481

Group type: COMPARATOR
Intervention: Glucagon
Number of subjects: 481
Study: 9000826

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (high and low doses)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Flurbiprofen
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both diclofenac sodium and flurbiprofen
Number of subjects: 40
Study: 1623700

Group type: EXPERIMENTAL
Intervention: Fluoride rinses with 0.2% neutral sodium fluoride
Number of subjects: 1306

Group type: COMPARATOR
Intervention: Distilled water (control group)
Number of subjects: 1306
Study: 6147693

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 484

Group type: COMPARATOR
Intervention: Cimetidine 400 mg
Number of subjects: 484
Study: 31743309

Group type: EXPERIMENTAL
Intervention: Real-time audiovisual feedback training
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group (standard CPR education models)
Number of subjects: 201
Study: 28165634

Group type: EXPERIMENTAL
Intervention: Ethosuximide
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 446
Study: 25118857

Group type: EXPERIMENTAL
Intervention: GI X-ray
Number of subjects: 1206

Group type: COMPARATOR
Intervention: GIE-ST
Number of subjects: 1206
Study: 23837574

Group type: EXPERIMENTAL
Intervention: 1 mg nebulized salbutamol in 4 mL of isotonic saline
Number of subjects: 13

Group type: COMPARATOR
Intervention: 5 mL of isotonic saline
Number of subjects: 13
Study: 21459891

Group type: EXPERIMENTAL
Intervention: Microalbuminuria
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Macroalbuminuria
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Non-diabetic patients
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Increased UACR
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: UACR
Number of subjects: 190
Study: 18379768

Group type: EXPERIMENTAL
Intervention: Perfusion MR imaging
Number of subjects: 33
Study: 16249073

Group type: EXPERIMENTAL
Intervention: Agomelatine (25 mg and 50 mg/day)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 14685736

Group type: EXPERIMENTAL
Intervention: Intervention program for caregivers
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not explicitly detailed)
Number of subjects: 40
Study: 10733168

Group type: EXPERIMENTAL
Intervention: CHIRON CMV gB subunit vaccine combined with MF59 adjuvant
Number of subjects: 0

Group type: COMPARATOR
Intervention: CMVIG manufactured from high titered plasma units
Number of subjects: 0
Study: 8737128

Group type: EXPERIMENTAL
Intervention: Sparfloxacin 200 mg once daily following a 400 mg loading dose on day 1
Number of subjects: 211

Group type: COMPARATOR
Intervention: Amoxycillin 1 g tid plus ofloxacin 200 mg bid
Number of subjects: 211
Study: 6713266

Group type: EXPERIMENTAL
Intervention: 2% epinephrine hydrochloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.1% dipivefrin hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29395526

Group type: EXPERIMENTAL
Intervention: Disposable-syringe jet injector (DSJI)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Needle-syringe (N-S)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 340
Study: 26864851

Group type: EXPERIMENTAL
Intervention: Telephone-based lifestyle behavioural intervention (10 individually tailored sessions over 6 months)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 160
Study: 25630474

Group type: EXPERIMENTAL
Intervention: Medial-oblique probe position
Number of subjects: 100

Group type: COMPARATOR
Intervention: Short-axis probe position
Number of subjects: 100
Study: 23748760

Group type: EXPERIMENTAL
Intervention: 1% trans fatty acids (TFA) dietary supplementation
Number of subjects: 65

Group type: COMPARATOR
Intervention: 0.04% trans fatty acids (TFA) dietary supplementation (control)
Number of subjects: 65
Study: 20937045

Group type: COMPARATOR
Intervention: rifaximin 1200 mg/day
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: rifaximin 1200 mg/day plus partially hydrolysed guar gum 5 g/day for 10 days
Number of subjects: 77
Study: 19017854

Group type: EXPERIMENTAL
Intervention: Soft Cast application
Number of subjects: 32
Study: 16326121

Group type: EXPERIMENTAL
Intervention: Single dose of salmeterol/fluticasone immediately before allergen challenge (T2)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone combination (50/250 mcg by Diskus) for 1 week and a single dose of salmeterol/fluticasone immediately before allergen challenge (T3)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo treatment and a single dose of placebo immediately before allergen challenge (T1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone combination (50/250 mcg by Diskus) for 1 week
Number of subjects: 9
Study: 12415061

Group type: EXPERIMENTAL
Intervention: Omalizumab (at least 0.016 mg/kg/IgE [IU/mL] per 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10613625

Group type: COMPARATOR
Intervention: Cholesteryl ester and phospholipid fractions
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Red cell fraction
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Triglyceride fraction
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Phospholipid and red cell fractions
Number of subjects: 1100
Study: 7497558

Group type: EXPERIMENTAL
Intervention: nicardipine 30 micrograms.kg‐1 iv (Group N, n = 12)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: diltiazem 0.3 mg.kg‐1 (Group D, n = 12)
Number of subjects: 37

Group type: COMPARATOR
Intervention: saline placebo (Group C, n = 13)
Number of subjects: 37
Study: 2023098

Group type: EXPERIMENTAL
Intervention: Ranitidine, 600 mg daily for 28 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (nontreated patients)
Number of subjects: 18
Study: 7259970

Group type: EXPERIMENTAL
Intervention: Facemask
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mouthpiece
Number of subjects: 15
Study: 31046826

Group type: EXPERIMENTAL
Intervention: Dialogic Book-sharing (DBS)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: ACT Raising Safe Kids Program (ACT)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Control group (neither intervention)
Number of subjects: 369
Study: 29073947

Group type: EXPERIMENTAL
Intervention: 30 months of dual antiplatelet therapy (DAPT)
Number of subjects: 25416

Group type: COMPARATOR
Intervention: 12 months of dual antiplatelet therapy (DAPT)
Number of subjects: 25416
Study: 26618848

Group type: EXPERIMENTAL
Intervention: $40 minigrant in the form of a voucher, valid at a local gardening store
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 23982170

Group type: EXPERIMENTAL
Intervention: CareLink(®) with diabetes-team initiated contact
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: CareLink(®) without diabetes-team initiated contact
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 70
Study: 21956772

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19640331

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/d for 4 weeks)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 17244765

Group type: EXPERIMENTAL
Intervention: Selegiline transdermal system (STS) 6 mg/24 h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alprazolam, Olanzapine, Risperidone (test drugs)
Number of subjects: 0
Study: 14699269

Group type: EXPERIMENTAL
Intervention: Prolotherapy injections (20% glucose/0.2% lignocaine)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Normal saline injections
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Flexion/extension exercises
Number of subjects: 110

Group type: COMPARATOR
Intervention: Normal activity
Number of subjects: 110
Study: 12131888

Group type: EXPERIMENTAL
Intervention: Composite (Z100)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Conventional glass ionomer cement (Fuji IX)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement (Fuji II LC)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Enamel
Number of subjects: 10
Study: 10372729

Group type: EXPERIMENTAL
Intervention: Weight Reduction (WR) with a very low calorie diet for 8-12 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Combined Oral Contraceptives (OC) treatment for 12 weeks
Number of subjects: 20
Study: 7502546

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (11 g/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Corn oil (CO) supplementation (11 g/day)
Number of subjects: 12
Study: 2248531

Group type: EXPERIMENTAL
Intervention: Amoxycillin (25 mg/kg/day) plus cimetidine for six weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Cimetidine alone
Number of subjects: 23
Study: 395255

Group type: EXPERIMENTAL
Intervention: Intranasal live allantoic influenza vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peroral live allantoic influenza vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 31511012

Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiochemotherapy in sarcopenic patients
Number of subjects: 61

Group type: COMPARATOR
Intervention: Neoadjuvant radiochemotherapy in non-sarcopenic patients
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Postoperative complications in sarcopenic patients
Number of subjects: 61

Group type: COMPARATOR
Intervention: Postoperative complications in non-sarcopenic patients
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Survival in sarcopenic patients
Number of subjects: 61

Group type: COMPARATOR
Intervention: Survival in non-sarcopenic patients
Number of subjects: 61
Study: 29393837

Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Perceived burdensomeness
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Thwarted belongingness
Number of subjects: 80
Study: 26403017

Group type: EXPERIMENTAL
Intervention: 2.4 atm abs breathing 100% oxygen
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham (1.3 atm-abs air)
Number of subjects: 50
Study: 23255270

Group type: EXPERIMENTAL
Intervention: Injection of 20 ml of normal saline into the knee joint cavity
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no joint infusion)
Number of subjects: 44
Study: 21362327

Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Diet (D)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Diet plus Exercise (DEX)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 93
Study: 19258409

Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Diet-endurance training
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Diet-resistance training
Number of subjects: 141
Study: 17597333

Group type: EXPERIMENTAL
Intervention: Short pulse width (60-90 micros)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Medium pulse width (120-150 micros)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Long pulse width (450 micros)
Number of subjects: 20
Study: 14693169

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplant
Number of subjects: 2

Group type: COMPARATOR
Intervention: Therapeutic anticoagulation
Number of subjects: 2
Study: 11069509

Group type: EXPERIMENTAL
Intervention: 50% dilution of fluticasone propionate (FP) 0.05% cream for 2 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 5%, 10%, and 25% dilutions of FP cream under wet wrap
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 0%, 5%, 10%, and 25% dilutions of FP cream applied on the whole body under wet wrap
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Measurements of 09.00 h serum cortisol after 2 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Measurements of 06.00 h serum cortisol levels
Number of subjects: 31
Study: 8850903

Group type: EXPERIMENTAL
Intervention: Pressure-reducing mattresses
Number of subjects: 0
Study: 1476055

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Occlusal splint therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Various additional therapies
Number of subjects: 80
Study: 6425893

Group type: EXPERIMENTAL
Intervention: Phospholipid liposomes (PL) 250 mg IV bolus plus additional 250 mg infused IV over 60 minutes
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3722852

Group type: EXPERIMENTAL
Intervention: RTU + instillation of Thiotepa
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: RTU followed by instillations of Adriamycin
Number of subjects: 135

Group type: COMPARATOR
Intervention: RTU alone
Number of subjects: 135
Study: 29843492

Group type: COMPARATOR
Intervention: 75 mg daily clopidogrel
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: 150 mg daily clopidogrel or triple therapy with clopidogrel and cilostazol
Number of subjects: 376
Study: 27388980

Group type: EXPERIMENTAL
Intervention: Intraoperative remifentanil (0.4 μg × kg−1 × min−1)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Intraoperative sufentanil (0.25 μg × kg−1 bolus, 0.15 μg × kg−1, repetition after 60 min)
Number of subjects: 23
Study: 24711073

Group type: EXPERIMENTAL
Intervention: 5 mg PHGG daily for 4 weeks
Number of subjects: 49
Study: 23583011

Group type: EXPERIMENTAL
Intervention: Lurasidone (40-160 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quetiapine XR (200-800 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quetiapine XR
Number of subjects: 0
Study: 20826963

Group type: EXPERIMENTAL
Intervention: High thoracic epidural analgesia (HTEA)
Number of subjects: 62
Study: 18696370

Group type: EXPERIMENTAL
Intervention: Expressive writing plus brief office intervention
Number of subjects: 196

Group type: COMPARATOR
Intervention: Brief office intervention
Number of subjects: 196
Study: 16873779

Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet
Number of subjects: 99

Group type: COMPARATOR
Intervention: ADA diet
Number of subjects: 99
Study: 15057387

Group type: EXPERIMENTAL
Intervention: 20% sucrose solution
Number of subjects: 11

Group type: COMPARATOR
Intervention: Distilled deionized water
Number of subjects: 11
Study: 10954063

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 8777332

Group type: COMPARATOR
Intervention: 8.2 kb Bam‐HI ALR2 genotype
Number of subjects: 128

Group type: COMPARATOR
Intervention: 8.2 kb allele
Number of subjects: 128

Group type: COMPARATOR
Intervention: 10/9.2-8.2 kb TCRBC-ALR2 genotype
Number of subjects: 128

Group type: COMPARATOR
Intervention: 10/9.2 and 9.2/9.2 kb TCRBC-ALR2 haplotypes
Number of subjects: 128
Study: 1599073

Group type: EXPERIMENTAL
Intervention: Music played through headphones from 5 min before induction of anaesthesia to 15 min postoperatively
Number of subjects: 50

Group type: COMPARATOR
Intervention: No music (control group)
Number of subjects: 50
Study: 6209194

Group type: EXPERIMENTAL
Intervention: Azatadine 2 X 1 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Terfenadine 2 X 60 mg daily
Number of subjects: 0
Study: 31492796

Group type: EXPERIMENTAL
Intervention: Online anticoagulation management model
Number of subjects: 496

Group type: COMPARATOR
Intervention: Offline anticoagulation management model
Number of subjects: 496
Study: 30485224

Group type: EXPERIMENTAL
Intervention: Postoperative lumbar drainage (LD)
Number of subjects: 170

Group type: COMPARATOR
Intervention: No lumbar drainage (control group)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Defect size measured intraoperatively
Number of subjects: 170
Study: 27974012

Group type: EXPERIMENTAL
Intervention: SWC+US (standard wound care + ultrasound)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: SWC+ES (standard wound care + electrical stimulation)
Number of subjects: 77

Group type: COMPARATOR
Intervention: SWC (standard wound care)
Number of subjects: 77
Study: 24604439

Group type: EXPERIMENTAL
Intervention: Contingency Telemedical Support (CTS)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study: 23008288

Group type: EXPERIMENTAL
Intervention: Multimarker reverse‐transcriptase quantitative polymerase chain reaction (RT‐qPCR) detection of circulating tumor cells (CTCs)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: BCG vaccine
Number of subjects: 331

Group type: COMPARATOR
Intervention: BCG placebo
Number of subjects: 331
Study: 19930174

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17990455

Group type: EXPERIMENTAL
Intervention: Modified Yanghe Decoction (YHD) combined with prednisone
Number of subjects: 61

Group type: COMPARATOR
Intervention: Prednisone alone (Control)
Number of subjects: 61
Study: 15605280

Group type: EXPERIMENTAL
Intervention: Whole-body bioelectrical impedance analysis
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Distal bioelectrical impedance analysis
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Proximal bioelectrical impedance analysis
Number of subjects: 200
Study: 12390596

Group type: EXPERIMENTAL
Intervention: Doxycycline monohydrate 100 mg daily tablet
Number of subjects: 522

Group type: COMPARATOR
Intervention: Chloroquine-proguanil (C/P) capsule
Number of subjects: 522
Study: 11052580

Group type: EXPERIMENTAL
Intervention: Tailored FEC regimen with G-CSF support (n=251)
Number of subjects: 525

Group type: COMPARATOR
Intervention: CTCb group (n=274)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Tailored FEC group (n=251)
Number of subjects: 525
Study: 8803666

Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate (specific dosing strategies not detailed)
Number of subjects: 0
Study: 1739192

Group type: EXPERIMENTAL
Intervention: Generic albuterol MDI (2 puffs, 180 micrograms)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Ventolin MDI (2 puffs, 180 micrograms)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Generic albuterol MDI (primed, 2 puffs)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Ventolin MDI (primed, 2 puffs)
Number of subjects: 17
Study: 6695835

Group type: EXPERIMENTAL
Intervention: Long-chain triglycerides (LCT)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Medium-chain triglycerides (MCT)
Number of subjects: 6
Study: 30216622

Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (TRT)
Number of subjects: 857

Group type: COMPARATOR
Intervention: Control group (not on TRT, Group 2a)
Number of subjects: 857
Study: 29181804

Group type: EXPERIMENTAL
Intervention: Vigorous intensity aerobic interval exercise (twice-weekly pre-operative supervised sessions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard treatment only (control group)
Number of subjects: 60
Study: 27058301

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens 0.625 mg/bazedoxifene 20 mg
Number of subjects: 1583

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens 0.45 mg/bazedoxifene 20 mg
Number of subjects: 1583

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens/medroxyprogesterone acetate
Number of subjects: 1583

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1583

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens/bazedoxifene
Number of subjects: 1583
Study: 24885828

Group type: EXPERIMENTAL
Intervention: Integrated care intervention for frail elderly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 21292793

Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide as a slow intravenous infusion over 15 min plus placebo (SIG)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide as an intravenous bolus infusion over 2 min plus placebo (BIG)
Number of subjects: 140
Study: 20528232

Group type: EXPERIMENTAL
Intervention: Oncovex(GM‐CSF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 18662969

Group type: EXPERIMENTAL
Intervention: R-CVP
Number of subjects: 321

Group type: COMPARATOR
Intervention: CVP
Number of subjects: 321
Study: 16288158

Group type: EXPERIMENTAL
Intervention: Folk play program (40 min, 5 times a week for 4 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (gymnastics and walking program)
Number of subjects: 33
Study: 12807615

Group type: EXPERIMENTAL
Intervention: Computer-based interactive video training (CS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lecture site training (LS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control site (CON)
Number of subjects: 0
Study: 12938523

Group type: EXPERIMENTAL
Intervention: Cimetidine (perioperative application)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (no drug given)
Number of subjects: 38
Study: 8697059

Group type: EXPERIMENTAL
Intervention: Isoproterenol injections, 3 times a week for 4 weeks, with diet and walking
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ointment containing forskolin, yohimbine, and aminophylline, applied 5 times a week for 4 weeks after hypertonic warm soaks, with diet and walking
Number of subjects: 70

Group type: COMPARATOR
Intervention: Forskolin ointment, applied 5 times a week for 4 weeks, with diet and walking
Number of subjects: 70

Group type: COMPARATOR
Intervention: Yohimbine ointment, applied 5 times a week for 4 weeks, with diet and walking
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Aminophylline ointment, 10%, applied 5 times a week for 6 weeks, with diet and walking
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Aminophylline cream, 2%, applied without diet or walking
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Aminophylline cream, 0.5%, applied without diet or walking
Number of subjects: 70
Study: 2334303

Group type: EXPERIMENTAL
Intervention: Oral administration of physostigmine under double-blind placebo-controlled conditions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0